Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report
Skin Cancer (Melanoma; Merkel cell carcinoma; Squamous cell carcinoma) 2018-2022
Official statistics in development
- Published
- 17 December 2024 (Latest release)
- Type
- Statistical report
About this release
This publication by the Cancer Medicines Outcomes Programme-Public Health Scotland collaboration reports on the outcomes of patients in Scotland who received immunotherapy or Immune Checkpoint Inhibitors (ICI) treatment for any type of skin cancer (melanoma; squamous cell carcinomas and Merkel cell carcinomas) between 1st January 2018 to 31st December 2022, with a follow up period until 30th September 2023. The data are reported for NHS Scotland and the three regional cancer networks for the three tumour sub-groups. We are continuing to develop this report and welcome feedback or user engagement in order to ensure the report is appropriate for stakeholders.
General enquiries
If you have an enquiry relating to this publication, please contact Julie Clarke at phs.cmop@phs.scot.
Media enquiries
If you have a media enquiry relating to this publication, please contact the Communications and Engagement team.
Requesting other formats and reporting issues
If you require publications or documents in other formats, please email phs.otherformats@phs.scot.
To report any issues with a publication, please email phs.generalpublications@phs.scot.
Older versions of this publication
Versions of this publication released before 16 March 2020 may be found on the Data and Intelligence, Health Protection Scotland or Improving Health websites.